Is metformin a primary ovulatory agent in patients with polycystic ovary syndrome? (Q36673559)

15 August 2017

1 reference

title

Is metformin a primary ovulatory agent in patients with polycystic ovary syndrome? (English)

1 reference

polycystic ovary syndrome

15 August 2017

1 reference

1 reference

1 reference

2

Susmeeta T Sharma

1 reference

15 August 2017

Kai I Cheang

1

1 reference

PubMed ID

17145645

15 August 2017

John E Nestler

series ordinal

3

1 reference

15 August 2017

1 November 2006

1 reference

Gynecological Endocrinology

15 August 2017

1 reference

15 August 2017

22

1 reference

15 August 2017

595-604

1 reference

15 August 2017

11

1 reference

Profound peripheral insulin resistance, independent of obesity, in polycystic ovary syndrome

15 August 2017

1 reference

https://api.crossref.org/works/10.1080%2F09513590601005847

A direct effect of hyperinsulinemia on serum sex hormone-binding globulin levels in obese women with the polycystic ovary syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F09513590601005847

Insulin enhancement of luteinizing hormone and follicle-stimulating hormone release by cultured pituitary cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F09513590601005847

Decreases in ovarian cytochrome P450c17 alpha activity and serum free testosterone after reduction of insulin secretion in polycystic ovary syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F09513590601005847

Suppression of serum insulin by diazoxide reduces serum testosterone levels in obese women with polycystic ovary syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F09513590601005847

Suppression of serum insulin level by diazoxide does not alter serum testosterone or sex hormone-binding globulin levels in healthy, nonobese women

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F09513590601005847

Effects of metformin on spontaneous and clomiphene-induced ovulation in the polycystic ovary syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F09513590601005847

Metformin in polycystic ovary syndrome: systematic review and meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F09513590601005847

Metformin therapy improves ovulatory rates, cervical scores, and pregnancy rates in clomiphene citrate-resistant women with polycystic ovary syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F09513590601005847

Effects of metformin on ovulation rate, hormonal and metabolic profiles in women with clomiphene-resistant polycystic ovaries: a randomized, double-blinded placebo-controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F09513590601005847

Metformin does not enhance ovulation induction in clomiphene resistant polycystic ovary syndrome in clinical practice

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F09513590601005847

Metformin increases the ovulatory rate and pregnancy rate from clomiphene citrate in patients with polycystic ovary syndrome who are resistant to clomiphene citrate alone

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F09513590601005847

Co-administration of metformin during rFSH treatment in patients with clomiphene citrate-resistant polycystic ovarian syndrome: a prospective randomized trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F09513590601005847

Prospective parallel randomized, double-blind, double-dummy controlled clinical trial comparing clomiphene citrate and metformin as the first-line treatment for ovulation induction in nonobese anovulatory women with polycystic ovary syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F09513590601005847

Effect of clomifene citrate plus metformin and clomifene citrate plus placebo on induction of ovulation in women with newly diagnosed polycystic ovary syndrome: randomised double blind clinical trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F09513590601005847

Revised 2003 consensus on diagnostic criteria and long-term health risks related to polycystic ovary syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F09513590601005847

A randomized controlled trial evaluating metformin pre-treatment and co-administration in non-obese insulin-resistant women with polycystic ovary syndrome treated with controlled ovarian stimulation plus timed intercourse or intrauterine inseminatio

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F09513590601005847

Sequential treatment of metformin and clomiphene citrate in clomiphene-resistant women with polycystic ovary syndrome: a randomized, controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F09513590601005847

Metformin administration versus laparoscopic ovarian diathermy in clomiphene citrate-resistant women with polycystic ovary syndrome: a prospective parallel randomized double-blind placebo-controlled trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F09513590601005847

Metabolic and ovarian effects of rosiglitazone treatment for 12 weeks in insulin-resistant women with polycystic ovary syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F09513590601005847

Endocrine and metabolic effects of rosiglitazone in non-obese women with polycystic ovary disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F09513590601005847

Effect of the insulin sensitizer pioglitazone on insulin resistance, hyperandrogenism, and ovulatory dysfunction in women with polycystic ovary syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F09513590601005847

Correction of insulin resistance and hyperandrogenism in polycystic ovary syndrome by combined rosiglitazone and clomiphene citrate therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F09513590601005847

Effect of rosiglitazone on spontaneous and clomiphene citrate-induced ovulation in women with polycystic ovary syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F09513590601005847

Responses of serum androgen and insulin resistance to metformin and pioglitazone in obese, insulin-resistant women with polycystic ovary syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F09513590601005847

Effects of metformin and rosiglitazone, alone and in combination, in nonobese women with polycystic ovary syndrome and normal indices of insulin sensitivity

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F09513590601005847

Hypersecretion of luteinizing hormone and the polycystic ovary syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F09513590601005847

Influence of serum luteinising hormone concentrations on ovulation, conception, and early pregnancy loss in polycystic ovary syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F09513590601005847

Hypersecretion of luteinising hormone, infertility, and miscarriage

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F09513590601005847

Recurrent early miscarriage and polycystic ovaries

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F09513590601005847

Hypersecretion of luteinizing hormone and ovarian steroids in women with recurrent early miscarriage.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F09513590601005847

Reduced serum glycodelin and insulin-like growth factor-binding protein-1 in women with polycystic ovary syndrome during first trimester of pregnancy

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F09513590601005847

Identification of placental protein 14 as an immunosuppressive factor in human reproduction

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F09513590601005847

Suppression by Human Placental Protein 14 of Natural Killer Cell Activity

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F09513590601005847

Paracrine actions of insulin-like growth factors and IGF binding protein-1 in non-pregnant human endometrium and at the decidual-trophoblast interface

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F09513590601005847

Insulin-like growth factor binding protein 1 stimulates cell migration and binds to the alpha 5 beta 1 integrin by means of its Arg-Gly-Asp sequence

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F09513590601005847

Plasminogen activators in tissue remodeling and invasion: mRNA localization in mouse ovaries and implanting embryos

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F09513590601005847

Plasminogen activator inhibitor 1 and miscarriage after metformin treatment and laparoscopic ovarian drilling in patients with polycystic ovary syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F09513590601005847

Continuing metformin throughout pregnancy in women with polycystic ovary syndrome appears to safely reduce first-trimester spontaneous abortion: a pilot study

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F09513590601005847

Pregnancy outcomes among women with polycystic ovary syndrome treated with metformin

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F09513590601005847

Height, weight, and motor-social development during the first 18 months of life in 126 infants born to 109 mothers with polycystic ovary syndrome who conceived on and continued metformin through pregnancy

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F09513590601005847

Metformin during pregnancy reduces insulin, insulin resistance, insulin secretion, weight, testosterone and development of gestational diabetes: prospective longitudinal assessment of women with polycystic ovary syndrome from preconception throughou

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F09513590601005847

Metformin reduces pregnancy complications without affecting androgen levels in pregnant polycystic ovary syndrome women: results of a randomized study

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F09513590601005847

10.1080/09513590601005847

21 January 2018

Identifiers

DOI

1 reference

15 August 2017

1 reference

PubMed ID

17145645